Item 8.01 Other Events.

On January 25, 2023, Inhibikase Therapeutics, Inc. (the "Company") issued a press release announcing that the full clinical hold on IkT-148009 in Parkinson's disease has been lifted by the U.S. Food and Drug Administration. A copy of the Company's press release regarding the lifting of the clinical hold is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

On January 25, 2023, the Company also issued a press release announcing the publication of studies describing the potential of IkT-148009 as a disease-modifying therapy for Parkinson's disease and related disorders. A copy of the Company's press release regarding the publication is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.



Number      Description

99.1          Press Release dated January 25, 2023 (Clinical Hold).

99.2          Press Release dated January 25, 2023 (Publication).

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses